| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
94,542,000 |
| Market
Cap: |
2.26(B) |
| Last
Volume: |
2,587,962 |
Avg
Vol: |
691,753 |
| 52
Week Range: |
$13.91 - $23.73 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 618 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
30,000 |
38,638 |
109,679 |
| Total Sell Value |
$0 |
$572,835 |
$771,595 |
$2,187,775 |
| Total People Sold |
0 |
1 |
2 |
3 |
| Total Sell Transactions |
0 |
1 |
2 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skovronsky Daniel |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,848 |
37,889 |
|
- |
|
| Hart Jayne B. |
Chief People Officer |
• – – |
2021-05-28 |
4 |
A |
$15.86 |
$17,162 |
D/D |
1,082 |
81,210 |
|
- |
|
| Haas Kevin Richard |
Chief Technology Officer |
• – – |
2021-05-28 |
4 |
A |
$15.86 |
$5,456 |
D/D |
344 |
56,113 |
|
- |
|
| Spiegelman Daniel K |
Director |
– • – |
2021-05-28 |
4 |
AS |
$28.99 |
$207,023 |
D/D |
(7,142) |
13,420 |
|
7% |
|
| Spiegelman Daniel K |
Director |
– • – |
2021-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,889) |
20,562 |
|
- |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-05-04 |
4 |
AS |
$31.97 |
$618,949 |
D/D |
(19,360) |
265,922 |
|
3% |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-05-04 |
4 |
OE |
$19.47 |
$376,939 |
D/D |
19,360 |
285,282 |
|
- |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-04-27 |
4 |
AS |
$31.47 |
$1,258,800 |
D/D |
(40,000) |
265,922 |
|
17% |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-04-27 |
4 |
OE |
$19.47 |
$778,800 |
D/D |
40,000 |
305,922 |
|
- |
|
| Lambert Nicole |
See Remarks |
• – – |
2021-04-19 |
4 |
AS |
$27.01 |
$179,586 |
D/D |
(6,649) |
129,119 |
|
23% |
|
| Santa Eric |
Chief Growth Officer |
• – – |
2021-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,420 |
16,420 |
|
- |
|
| Hart Jayne B. |
Chief People Officer |
• – – |
2021-03-29 |
4 |
AS |
$30.00 |
$1,740,000 |
D/D |
(58,000) |
80,128 |
|
19% |
|
| Hart Jayne B. |
Chief People Officer |
• – – |
2021-03-29 |
4 |
OE |
$19.47 |
$1,291,860 |
D/D |
58,000 |
88,162 |
|
- |
|
| Verratti Mark |
President, Myriad Neuroscience |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
15,441 |
157,130 |
|
- |
|
| Jackson Benjamin |
E.V.P., General Counsel |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
18,879 |
107,029 |
|
- |
|
| Diaz Paul J |
President and CEO |
• • – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
159,915 |
458,869 |
|
- |
|
| Haas Kevin Richard |
Chief Technology Officer |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
13,326 |
55,769 |
|
- |
|
| Parkinson Paul |
EVP Strategy and Innovation |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,661 |
87,407 |
|
- |
|
| Riggsbee Richard Bryan |
Chief Financial Officer |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
32,774 |
339,925 |
|
- |
|
| Lambert Nicole |
President, Myriad Oncology, |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
29,556 |
135,768 |
|
- |
|
| Hart Jayne B. |
Chief People Officer |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
13,326 |
80,128 |
|
- |
|
| Lanchbury Jerry S |
Chief Scientific Officer |
• – – |
2021-03-24 |
4 |
A |
$0.00 |
$0 |
D/D |
19,347 |
265,922 |
|
- |
|
| Haas Kevin Richard |
SVP TechnologyOfficer |
• – – |
2021-02-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
32,443 |
|
3% |
|
| Ancona Margaret |
SVP Enterprise Transformation |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Riggsbee Richard Bryan |
Chief Financial Officer |
• – – |
2021-02-18 |
4 |
D |
$29.69 |
$331,786 |
D/D |
(11,175) |
307,151 |
|
- |
|
1303 Records found
|
|
Page 11 of 53 |
|
|
4.17 (21.08%) 
